Business
Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference on Molecu...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"\n \n \n \n Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\ntable p, #divContent table p\n{\nmargin: 0px;\nmargin-left: 3.8px;\nfont-size: 8pt !important;\nfont-family: Arial;\ncolor: black;\nmargin-right: 0pt;\n}\ntable th, #divContent table th\n{\nfont-weight: unset !important;\ntext-align: unset !important;\nvertical-align: unset !important;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VANCOUVER, BC\n \n \n ,\n \n \n Aug. 17, 2021\n \n \n /CNW/ - Rakovina Therapeutics Inc. (TSXV: RKV) (\"the Company\"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its abstract entitled\n \n \n In Vitro\n \n \n \n Activity and Efficacy of Novel Dual PARP-HDAC Inhibitors\n \n has been accepted for presentation at the upcoming joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.\n \n \n \n \n \n \n \n \n \n Hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC), the 2021 Molecular Targets and Cancer Therapeutics conference will take place as a virtual event\n \n October 7-10, 2021\n \n . The conference has historically attracted academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.\n \n \n \"We look forward to presenting our work in developing precision medicines that selectively target and kill tumor cells at this prestigious meeting,\" said Prof.\n \n Mads Daugaard\n \n , Rakovina Therapeutics' president and chief scientific officer.  \"The meeting will represent the first opportunity to highlight promising new data being developed around our novel kt-3000 series of dual PARP-HDAC inhibit...